|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1987-3-13
|
|
pubmed:abstractText |
A phase II trial of cytarabine, cisplatin, and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin's lymphoma. There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0361-5960
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
187-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:3802114-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3802114-Cisplatin,
pubmed-meshheading:3802114-Cytarabine,
pubmed-meshheading:3802114-Drug Evaluation,
pubmed-meshheading:3802114-Etoposide,
pubmed-meshheading:3802114-Female,
pubmed-meshheading:3802114-Hematologic Diseases,
pubmed-meshheading:3802114-Humans,
pubmed-meshheading:3802114-Lymphoma, Non-Hodgkin,
pubmed-meshheading:3802114-Male
|
|
pubmed:year |
1987
|
|
pubmed:articleTitle |
Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
